We have observed
5 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after November 30, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
AUTOIMMUNE AND INFLAMMATORY DISORDER THERAPY
THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES
THERAPEUTICALLY ACTIVE OXAZOLINE DERIVATIVES
Purine analogues and their use as immunosuppressive agents
THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES